People infected with the coronavirus were significantly more likely to be diagnosed with Type 2 diabetes within a year of their infection, compared with those who had not been exposed to the virus, researchers in Canada reported Tuesday.

Men were more likely to develop diabetes than women, the scientists found. People who were so sick that they were hospitalized were more than twice as likely to go on to a diabetes diagnosis, compared with those who were not infected.

People who were admitted to intensive care were more than three times as likely to develop diabetes, the researchers also found. The findings add to a growing body of evidence about COVID’s long-term effects.

“This is definitely a concern in terms of long-term outcomes,” said Dr. Naveed Z. Janjua, the paper’s senior author and a professor at the School of Population and Public Health at University of British Columbia.

“With a respiratory infection, you usually think, ‘Seven or eight days, and I’m done with it; that’s it,’” he added. “Here we’re seeing lingering effects that are lifelong.”

The study, published in JAMA Network Open, used a large data set from British Columbia to compare diabetes diagnoses among more than 125,000 individuals who had tested positive for COVID in 2020 and 2021 with those of more than 500,000 unexposed individuals during the same period.

Mpox still circulating more than you'd think, from hot spot in Mexico to cluster of cases in Canada | CBC News The World Health Organization made the call this week to maintain mpox as a public health emergency — and later noted the number of new cases reported globally increased by 70 per cent from the week before. A cluster of cases in Toronto, too, offers a reminder that transmission is still simmering. CBC

...

COVID vaccination in pregnancy may benefit both moms and infants CIDRAP

Pregnant women can reduce their infant's risk of COVID-related hospitalization by receiving at least two doses of an mRNA vaccine, which are highly effective against maternal Delta variant infection and moderately effective against maternal and infant Omicron infection, suggests a study published yesterday in BMJ. A third (booster) dose offered added protection against Omicron.